BAGLIVO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 489
EU - Europa 295
AS - Asia 172
Totale 956
Nazione #
US - Stati Uniti d'America 488
IE - Irlanda 108
IT - Italia 82
SG - Singapore 72
CN - Cina 48
HK - Hong Kong 40
RO - Romania 27
DE - Germania 24
FI - Finlandia 13
RU - Federazione Russa 12
FR - Francia 10
KR - Corea 7
CH - Svizzera 4
GB - Regno Unito 4
AT - Austria 2
GR - Grecia 2
IN - India 2
UA - Ucraina 2
UZ - Uzbekistan 2
BE - Belgio 1
HU - Ungheria 1
MX - Messico 1
NL - Olanda 1
PH - Filippine 1
RS - Serbia 1
SE - Svezia 1
Totale 956
Città #
Chandler 145
Dublin 108
Singapore 52
Hong Kong 40
San Mateo 35
Boardman 34
Santa Clara 29
Bucharest 27
Perugia 26
Altamura 21
Lawrence 20
Medford 20
Princeton 20
Beijing 16
Ann Arbor 14
Munich 14
Andover 11
Wilmington 11
Des Moines 9
Helsinki 9
Seoul 7
San Paolo di Civitate 6
Redmond 5
Arezzo 4
Dearborn 4
Nanjing 4
Saint Petersburg 4
Houston 3
Rome 3
Faenza 2
Los Angeles 2
New York 2
Paris 2
Redwood City 2
Simi Valley 2
Terni 2
Amelia 1
Amsterdam 1
Angeles 1
Aprilia 1
Ashburn 1
Asso 1
Azcapotzalco 1
Brussels 1
Changsha 1
Chaoyang 1
Chicago 1
Dallas 1
Fairfield 1
Falls Church 1
Frankfurt am Main 1
Guangzhou 1
Guttingen 1
Kunming 1
Lappeenranta 1
Mozzo 1
Mumbai 1
Nagold 1
Nanchang 1
Norwalk 1
Padova 1
Seattle 1
Sterling 1
Szeged 1
Tianjin 1
Vienna 1
Xian 1
Totale 746
Nome #
Non-coding RNAs in lung cancer 63
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 61
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 60
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 58
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 54
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 54
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 53
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 50
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 50
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 50
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 49
Osimertinib 48
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 47
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 44
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 44
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 44
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 43
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 41
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 30
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 29
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 22
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 13
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 13
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 12
Totale 1.032
Categoria #
all - tutte 5.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.346


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 0 0 0 4 4 3 2 7 17 7 0
2020/202154 2 1 2 0 33 1 1 6 3 1 4 0
2021/2022170 1 25 1 5 4 3 1 47 2 22 24 35
2022/2023398 22 75 9 37 38 40 0 18 142 0 14 3
2023/2024158 8 10 16 6 2 2 39 1 4 5 36 29
2024/2025129 10 31 31 12 45 0 0 0 0 0 0 0
Totale 1.032